Functional Characterization of 22 CYP 3A4 Protein Variants to Metabolize Ibrutinib In Vitro

• Published in: Basic & clinical pharmacology & toxicology 2018-04, Vol.122 (4), p.383-387
• Main Authors: Xu, Ren‐ai, Wen, Jian, Tang, Pengfei, Wang, Chenchen, Xie, Saili, Zhang, Bo‐wen, Zhou, Quan, Cai, Jian‐ping, Hu, Guo‐xin
• Format: Article
• Language: English
• ISSN: 1742-7835; 1742-7843
• DOI: 10.1111/bcpt.12934

Cytochrome P450 3A4 ( CYP 3A4) is quantitatively the most important P450 enzyme in adults. It is suggested that CYP 3A4 genetic polymorphisms may influence the rate of the metabolism and elimination of CYP 3A4 substrates in human beings. Ibrutinib is an anticancer drug and primarily metabolized by CYP 3A4. The aim of this study was to systematically investigate the effects of 22 CYP 3A4 protein variants on the metabolism of ibrutinib in vitro . When compared with wild‐type CYP 3A4.1, two variants ( CYP 3A4.17 and CYP 3A4.24) had no detectable enzyme activity; five variants ( CYP 3A4.10, .11, .18, .23 and .33) exhibited no significant differences; another five variants ( CYP 3A4.3, .4, .9, .19 and .34) showed increased intrinsic clearance values, while the remaining nine variants ( CYP 3A4.2, .5, .14, .15, .16, .28, .29, .31 and .32) displayed decreased enzymatic activities in different degrees. As the first study of 22 CYP 3A4 protein variants in ibrutinib metabolism, these comprehensive data may help in the clinical assessment of the metabolism and elimination of ibrutinib and also offer a reference to the personalized treatment of ibrutinib in clinic.